Journal of Clinical & Experimental Pharmacology

Carlos Vila Silván

Publications

• Research Article
  Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity
  Author(s): Celia Oreja-Guevara*,Bonaventura Casanova,Carlos Manuel Ordás,Carlos Vila Silván,David Asensio,Mariona MassanaCelia Oreja-Guevara*,Bonaventura Casanova,Carlos Manuel Ordás,Carlos Vila Silván,David Asensio,Mariona Massana
  
  Abstract Background: Subsequent to introduction in June 2010 in the United Kingdom and Spain of tetrahydrocannabinol (THC) : cannabidiol (CBD) oromucosal spray (Sativex®) for management of multiple sclerosis (MS) spasticity, and as part of a wider initiative to address British health authority requirements for post-marketing surveillance to identify possible short- and long-term risks associated with its use as a condition of marketing authorization, studies were undertaken to evaluate the safety of THC: CBDspray under clinical practice conditions. Methods: This prospective, observational, multicentre study reports on 205 patients with treatment-resistant MS spasticity who were prescribed THC: CBD spray as add-on therapy to existing antispasticity medications at 13 specialist MS centres across Spain. Safety evaluations were performed after 6 and 12 months’ exposure to THC: C.. View More»
  DOI: 10.4172/2161-1459.1000184

  Abstract PDF